
Opinion|Videos|February 26, 2024
LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer
Dr. Chapin and fellow expert oncologists discuss the latest data from the LIGHTHOUSE trial, evaluating 18F-rhPSMA-7.3 for staging patients with prostate cancer.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
4
FDA approves first-line Zenflow system for the treatment of BPH
5



















